Perfluorocarbon compounds applications in diagnostic imaging

Research output: Contribution to journalArticle

Abstract

Perfluorocarbon compounds (PFC's), well known in industry and of late as synthetic oxygen carriers, have a wide range of significant applications in diagnostic imaging. Their enhancement effect is detectable by ultrasound and magnetic resonance and if radiopaque, such as perfluoroctylbromide (PFOB), by standard radiography and computed tomography (CT). We have utilized PFOB as a CT contrast agent to enhance the blood pool, and as both a CT and an ultrasound contrast agent to enhance the liver, spleen, abscesses, infarctions, and tumors or any tissue where inflammatory cells can be found. PFC's, except for the echogenic enhancement of the vascular space on their first pass to the lung, do not enhance the blood pool on ultrasound. Otherwise, ultrasound applications are similar to those observed for CT. Fluosol, which was available for human trials, is not radiopaque and therefore served as an ultrasound contrast agent. In a preliminary clinical trial, Fluosol produced tumor enhancement in man at 1.6g/kg allowing the visualization of previously missed lesions and liver and spleen enhancement at 2.4g/kg allowing the visualization of previously missed non-enhancing lesions. Perfluorocarbon toxicity seems to be related to the constituents of the emulsion rather than the perfluorocarbon itself. Improvements in the emulsifier and emulsification technology has yielded stable emulsions at high concentrations and low toxicity.

Original languageEnglish (US)
Pages (from-to)18-23
Number of pages6
JournalProceedings of SPIE - The International Society for Optical Engineering
Volume626
DOIs
StatePublished - Jun 12 1986

Fingerprint

Fluorocarbons
Ultrasound
Computed Tomography
Diagnostics
tomography
Ultrasonics
Imaging
Tomography
Imaging techniques
Enhancement
spleen
augmentation
Contrast Media
liver
toxicity
Emulsion
lesions
emulsions
blood
Toxicity

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Condensed Matter Physics
  • Computer Science Applications
  • Applied Mathematics
  • Electrical and Electronic Engineering

Cite this

@article{18c26d83970d43d2b42632b18f3f5c1f,
title = "Perfluorocarbon compounds applications in diagnostic imaging",
abstract = "Perfluorocarbon compounds (PFC's), well known in industry and of late as synthetic oxygen carriers, have a wide range of significant applications in diagnostic imaging. Their enhancement effect is detectable by ultrasound and magnetic resonance and if radiopaque, such as perfluoroctylbromide (PFOB), by standard radiography and computed tomography (CT). We have utilized PFOB as a CT contrast agent to enhance the blood pool, and as both a CT and an ultrasound contrast agent to enhance the liver, spleen, abscesses, infarctions, and tumors or any tissue where inflammatory cells can be found. PFC's, except for the echogenic enhancement of the vascular space on their first pass to the lung, do not enhance the blood pool on ultrasound. Otherwise, ultrasound applications are similar to those observed for CT. Fluosol, which was available for human trials, is not radiopaque and therefore served as an ultrasound contrast agent. In a preliminary clinical trial, Fluosol produced tumor enhancement in man at 1.6g/kg allowing the visualization of previously missed lesions and liver and spleen enhancement at 2.4g/kg allowing the visualization of previously missed non-enhancing lesions. Perfluorocarbon toxicity seems to be related to the constituents of the emulsion rather than the perfluorocarbon itself. Improvements in the emulsifier and emulsification technology has yielded stable emulsions at high concentrations and low toxicity.",
author = "Mattrey, {Robert F.}",
year = "1986",
month = "6",
day = "12",
doi = "10.1117/12.975372",
language = "English (US)",
volume = "626",
pages = "18--23",
journal = "Proceedings of SPIE - The International Society for Optical Engineering",
issn = "0277-786X",
publisher = "SPIE",

}

TY - JOUR

T1 - Perfluorocarbon compounds applications in diagnostic imaging

AU - Mattrey, Robert F.

PY - 1986/6/12

Y1 - 1986/6/12

N2 - Perfluorocarbon compounds (PFC's), well known in industry and of late as synthetic oxygen carriers, have a wide range of significant applications in diagnostic imaging. Their enhancement effect is detectable by ultrasound and magnetic resonance and if radiopaque, such as perfluoroctylbromide (PFOB), by standard radiography and computed tomography (CT). We have utilized PFOB as a CT contrast agent to enhance the blood pool, and as both a CT and an ultrasound contrast agent to enhance the liver, spleen, abscesses, infarctions, and tumors or any tissue where inflammatory cells can be found. PFC's, except for the echogenic enhancement of the vascular space on their first pass to the lung, do not enhance the blood pool on ultrasound. Otherwise, ultrasound applications are similar to those observed for CT. Fluosol, which was available for human trials, is not radiopaque and therefore served as an ultrasound contrast agent. In a preliminary clinical trial, Fluosol produced tumor enhancement in man at 1.6g/kg allowing the visualization of previously missed lesions and liver and spleen enhancement at 2.4g/kg allowing the visualization of previously missed non-enhancing lesions. Perfluorocarbon toxicity seems to be related to the constituents of the emulsion rather than the perfluorocarbon itself. Improvements in the emulsifier and emulsification technology has yielded stable emulsions at high concentrations and low toxicity.

AB - Perfluorocarbon compounds (PFC's), well known in industry and of late as synthetic oxygen carriers, have a wide range of significant applications in diagnostic imaging. Their enhancement effect is detectable by ultrasound and magnetic resonance and if radiopaque, such as perfluoroctylbromide (PFOB), by standard radiography and computed tomography (CT). We have utilized PFOB as a CT contrast agent to enhance the blood pool, and as both a CT and an ultrasound contrast agent to enhance the liver, spleen, abscesses, infarctions, and tumors or any tissue where inflammatory cells can be found. PFC's, except for the echogenic enhancement of the vascular space on their first pass to the lung, do not enhance the blood pool on ultrasound. Otherwise, ultrasound applications are similar to those observed for CT. Fluosol, which was available for human trials, is not radiopaque and therefore served as an ultrasound contrast agent. In a preliminary clinical trial, Fluosol produced tumor enhancement in man at 1.6g/kg allowing the visualization of previously missed lesions and liver and spleen enhancement at 2.4g/kg allowing the visualization of previously missed non-enhancing lesions. Perfluorocarbon toxicity seems to be related to the constituents of the emulsion rather than the perfluorocarbon itself. Improvements in the emulsifier and emulsification technology has yielded stable emulsions at high concentrations and low toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84957478063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957478063&partnerID=8YFLogxK

U2 - 10.1117/12.975372

DO - 10.1117/12.975372

M3 - Article

AN - SCOPUS:84957478063

VL - 626

SP - 18

EP - 23

JO - Proceedings of SPIE - The International Society for Optical Engineering

JF - Proceedings of SPIE - The International Society for Optical Engineering

SN - 0277-786X

ER -